You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Under the agreement, Genetron gains exclusive rights to develop and commercialize minimal residual disease assays using ImmuQuad's immunogenomics technology.
Under a licensing deal, Omixon will sell the AzureSeq-200 RT-PCR kit under its brand in Europe, the Middle East, and Africa.
Under the non-exclusive license, Quanterix will receive an initial license fee, milestone fees and launch milestones, and royalties.
The company licensed nasopharyngeal swab and toehold switch molecular detection technologies from the Wyss Institute to develop SARS-CoV-2 diagnostics.
Oncocyte is licensing Chronix's blood-based copy number instability test, and Chronix will help commercialize Oncocyte's DetermaRx in the EU through its German lab.
The blood test will be available to specialty and primary care physicians across the US and Canada from LabCorp by early 2021.
Under the agreement, DiaSorin will make the test, which distinguishes between viral and bacterial infections, available on its Liaison analyzer platform.
The point-of-care test is based on technology developed at the Columbia University Fertility Center for preimplantation genetic testing.
The expanded license from MIT includes clinical applications for the technology, with PathSensors initially targeting SARS-CoV-2 detection.
Developed by the Ragon Institute, the ELISA-based test measures antibodies that bind to the receptor binding domain of the SARS-CoV-2 spike protein.